Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Multiple Myeloma (Nov 2020)

Posted by Matt Breese on Nov 20, 2020

Find me on:

According to our recent payer coverage analysis for multiple myeloma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for multiple myeloma treatments shows that under the pharmacy benefit, about 51% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Multiple Myeloma-4Q2020Data snapshot as of Q4 2020

Trends: In August 2020, the FDA gave accelerated approval to GlaxoSmithKline’s Blenrep (belantamab mafodotin-blmf) for adults with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunotherapy agent.  

To read the full Reality Check on Multiple Myeloma treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing